TCR2 THERAPEUTICS INC.·4

Dec 11, 6:11 AM ET

Hofmeister Robert 4

4 · TCR2 THERAPEUTICS INC. · Filed Dec 11, 2020

Insider Transaction Report

Form 4
Period: 2020-12-10
Hofmeister Robert
Chief Scientific Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2020-12-10+76,00076,000 total
    Exercise: $31.83Exp: 2030-12-09Common Stock (76,000 underlying)
Holdings
  • Common Stock

    38,850
Footnotes (1)
  • [F1]25% of this option shall vest and become exercisable on January 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION